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Abstract Attenuated and heat-killed mycobacteria dis-
play demonstrable activity against cancer in the clinic;
however, the induced immune response is poorly character-
ised and potential biomarkers of response ill-deWned. We
investigated whether three mycobacterial preparations cur-
rently used in the clinic (BCG and heat-killed Mycobacte-
rium vaccae and Mycobacterium obuense) can stimulate
anti-tumour eVector responses in human  T-cells. 
T-cell responses were characterised by measuring cytokine
production, expression of granzyme B and cytotoxicity
against tumour target cells. Results show that  T-cells are
activated by these mycobacterial preparations, as indicated
by upregulation of activation marker expression and prolif-
eration. Activated  T-cells display enhanced eVector
responses, as shown by upregulated granzyme B expres-
sion, production of the TH1 cytokines IFN- and TNF-,
and enhanced degranulation in response to susceptible and
zoledronic acid-treated resistant tumour cells. Moreover, 
T-cell activation is induced by IL-12, IL-1 and TNF-
from circulating type 1 myeloid dendritic cells (DCs), but
not from type 2 myeloid DCs or plasmacytoid DCs. Taken
together, we show that BCG, M. vaccae and M. obuense
induce  T-cell anti-tumour eVector responses indirectly
via a speciWc subset of circulating DCs and suggest a mech-
anism for the potential immunotherapeutic eVects of BCG,
M. vaccae and M. obuense in cancer.
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Introduction
The immune system’s intrinsic ability to recognise and
destroy tumour cells is an attractive target for therapeutic
intervention. Moreover, cancer patients are often immuno-
compromised due to the immunosuppressive nature of the
tumour and collateral aVects of certain chemotherapies.
Cancer immunotherapy aims to bolster appropriate anti-
tumour immune responses; an approach that has great
potential as a stand-alone treatment or combinatorial part-
ner of standard chemotherapy. Indeed, cancer immunother-
apy has had many successes, with one of the most
prominent milestones to date being the use of Bacillus Cal-
mette Guérin (BCG) to treat bladder cancer [1].
The remarkable success of BCG therapy in bladder can-
cer highlights the potential for mycobacterial preparations as
cancer immunotherapeutic agents or as adjuvants to existing
chemotherapies. There has also been considerable interest in
a heat-killed preparation of Mycobacterium vaccae for the
treatment of cancers of the prostate, lung, kidney and skin
[2–5]. In particular, M. vaccae combined with chemother-
apy increased survival and improved quality of life in phase
III trials for adenocarcinoma of the lung [6, 7]. Recently,
attention has turned to heat-killed preparations of M. obu-
ense, which are currently undergoing early phase trials in
melanoma [8]. Although mycobacterial preparations are cur-
rently under clinical investigation, mechanistic studies are
limited and biomarkers of response ill-deWned, which is
hampering their success. In vitro studies are needed to iden-
tify candidate immune cells for immunological monitoring
during clinical trials.  T-cells have a number of properties
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that highlight them as a potential mechanism by which
mycobacterial preparations elicit their anti-cancer eVects. In
particular,  T-cells play a demonstrable role in protective
immunosurveillance against cancer [9–11]; are highly reac-
tive against mycobacterial antigens [12]; and display potent
cross-reactivity against tumour cells and mycobacteria [13].
However, the capacity for clinical preparations of BCG, M.
vaccae and M. obuense to elicit eVector responses in 
T-cells has been largely overlooked and remains poorly
characterised.
 T-cells can elicit protective immune responses against
cancer and are an essential component of the anti-tumour
immune response. In vitro, human  T-cells display potent
cytotoxicity against tumour cells from a broad range of epi-
thelial and haematalogic malignancies [14–16]. They also
produce interferon (IFN)- and tumour necrosis factor
(TNF)- in response to mycobacteria and tumour, which
potentiate protective cell-mediated immune responses
against cancer [17]. Moreover,  T-cell responses to anti-
genic challenge are rapid and memory-like, thus providing
an early defence mechanism that complements the delayed
immune response of  T-cells [18]. In contrast to 
T-cells,  T-cells recognise phosphoantigens independently
of major histocompatibility complex (MHC) class I, which
is often down-modulated in a range of cancers, thus rein-
forcing the value of  T-cells in cancer immunotherapy
[19].  T-cells also express the natural killer activatory
receptor NKG2D; this receptor interacts with MHC class
I-related stress molecules such as MICA and MICB, which
are frequently upregulated on tumours [20].
Our aim was to examine whether BCG and heat-killed
M. vaccae and M. obuense can prime  T-cells for an anti-
tumour eVect. Data presented herein suggest that these
mycobacterial preparations stimulate anti-tumour responses
in  T-cells, as shown by production of TH1 cytokines,
upregulation of granzyme B and increased cytotoxicity
against tumour cells. Furthermore, data suggest that 
T-cell responses are indirectly stimulated by IL-12, IL-1
and TNF- from circulating type 1 myeloid dendritic cells
(mDC1s). Taken together, our study is the Wrst to demon-
strate that BCG, M. vaccae and M. obuense may enhance
the eVector responses of  T-cells by stimulating mDC1s
to produce IL-12, IL-1 and TNF-, which sheds light on
the mechanism of action for the anti-cancer eVects of these
immunotherapies.
Materials and methods
Mycobacteria
Heat-killed M. vaccae and M. obuense were supplied by
Professor John Stanford (University College London).
Mycobacteria were heat-killed by autoclaving at 121°C for
15 min in borate-buVered solution. Lyophilised BCG vac-
cine (Danish strain 1331; Statens Serum Institut) was resus-
pended in phosphate-buVered saline (PBS; Sigma) and
heat-killed as described above. Mycobacteria were added to
cell cultures using optimised doses of 1 £ 105 culturable
particles/ml BCG, 100 g/ml  M. vaccae and 100 g/ml
M. obuense (supplementary Wg. 1).
Cell isolation/depletion
Peripheral blood mononuclear cells (PBMCs) were isolated
from healthy donors by density-adjusted centrifugation using
Histopaque ¡1,077 (Sigma). Contaminating red blood cells
were lysed with hypotonic ammonium chloride (5 Prime) and
platelets removed by centrifugation at 200 g. SpeciWc cell
populations were isolated or depleted from PBMCs using
magnetic microbeads against TCR, CD14, CD4, CD8,
CD19, CD56 and/or CD1c (Miltenyi Biotec) according to the
manufacturer’s instructions. Purities for cell isolations were
analysed by Xow cytometry and were consistently >95%.
Cell culture
All cell cultures were performed at 37°C with 5% CO2.
1 £ 106 PBMCs in 200 l complete medium RPMI-1640
(Sigma) with 5% heat-inactivated human A/B serum
(Lonza) and 2 mM L-glutamine (Sigma), were cultured in
96-well, Xat-bottomed tissue culture plates. For prolifera-
tion assays, PBMCs were stained with 400 nM carboxy-
Xuorescein diacetate succinimidyl ester (CFSE; Invitrogen)
and 1 £ 106 cells in 1 ml of complete medium cultured in
24-well tissue culture plates for 6 days. The percentage of
cells with CFSE Xuorescence lower than the untreated con-
trols was used as a measure of proliferation. 2–5 £ 104
puriWed  T-cells in 200 l of complete medium were cul-
tured in 96-well, round-bottomed tissue culture plates alone
or with CD56+, CD4+, CD8+ or CD1c+ cells. For some
experiments,   T-cells were cultured overnight with
recombinant human IL-12 (Miltenyi Biotec), IL-1 and
TNF- (both Peprotech) at concentrations indicated in
Wgure legends. 1 £ 106 CD4+ cells in 200 l complete
medium were cultured in 96-well, Xat-bottomed tissue cul-
ture plates. For some experiments, supernatants were col-
lected and passed through 0.2-m Wlters prior to use. For
intracellular cytokine staining, 1 g/ml of Brefeldin A
(Sigma) was added for the last 4 h of culture.
The following positive controls were used: isopentenyl
pyrophosphate (IPP; 10 g/ml); phorbol myristate acetate
(PMA; 25 ng/ml); ionomycin (I; 1 g/ml); phytohaemag-
glutinin-leucoagglutinin (PHA-L; 1 g/ml); lipopolysac-
charide (LPS; E. coli-derived; 1 g/ml); R848 (2.5 g/ml)
(all from Sigma); and IL-2 (5U/ml; Peprotech).Cancer Immunol Immunother (2012) 61:535–547 537
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The Burkitt’s Lymphoma cell line Daudi and lung carci-
noma cell line A549 (both ECACC) were cultured in
RPMI-1640 or Dulbecco’s modiWed eagle media (DMEM;
Sigma), respectively, supplemented with 10% foetal bovine
serum (FBS; Invitrogen) and 2 mM L-glutamine. 2 £ 106
A549 cells were added per 75 cm2 tissue culture Xask and
allowed to adhere for 24 h prior to overnight culture with
0.1, 1 or 10 M of zoledronic acid (Novartis).
Flow cytometry
Cells were stained in buVer (PBS with 1% albumin bovine
serum (Sigma) and 0.1% sodium azide (Sigma) for 30 min
at 4°C with the following monoclonal antibodies: CD3-
FITC, CD3-PERCP, TCR-PE, V2-PE, CD69-FITC,
CD69-PE, CD69-APC, HLA-DR-PERCP, CD25-APC,
CD4-PE, CD123-PE, CD123-PECy5 and CD14-APC (all
from Becton–Dickinson); CD11c-FITC, CD11c-PE and
CD1c-PE (all from Miltenyi Biotec); and V1-FITC
(Thermo ScientiWc). Matched isotype control antibodies
were used to determine background staining. Cells were
then Wxed in 4% paraformaldehyde (BD CellWx; Becton–
Dickinson) for 20 min at 4°C. For intracellular cytokine
staining, cells were simultaneously Wxed and permeabilised
in 4% paraformaldehyde and 0.1% saponin (BD CytoWx/
Cytoperm; Becton–Dickinson) for 20 min at 4°C and then
resuspended in 0.1% saponin with IFN--APC, TNF--
APC, IL-10-APC, IL-12-APC (all from Miltenyi Biotec),
IFN--PECy7 (Becton–Dickinson), IL-1-APC (R and D
Systems) or Granzyme B-APC (Caltag-Medsystems) for
10 min at room temperature. Expression levels were ana-
lysed using FACsCalibur or LSRII with CellQuest Pro or
FACs DIVA software, respectively (all Becton–Dickinson).
Tritiated 3H incorporation
Tritiated [3H]-thymidine incorporation was used to assess
proliferation of puriWed  T-cells. Cells were cultured with
mycobacteria for 6 days prior to the addition of 2.5 Ci/ml
[3H]-thymidine (GE Healthcare) for the last 18 h of culture.
Cells were osmotically lysed and DNA collected onto
Wlters (Perkin Elmer). Scintillation Xuid (Perkin Elmer) was
added prior to measuring beta emission (photon counts per
minute) using a liquid scintillation counter (Perkin Elmer).
Cytokine analysis of culture supernatants
TH1/TH2 cytometric bead arrays (CBAs; Becton–Dickinson)
were used to measure the concentration of IFN-, TNF-,
IL-10, IL-5, IL-4 and IL-2 in cell culture supernatants
according to the manufacturer’s instructions. Supernatants
were also analysed by multi-analyte proWling of inXamma-
tion-related analytes by Rules Based Medicine (USA).
Cytotoxicity assays
Mycobacteria-stimulated PBMCs were co-cultured with
Daudi or zoledronic acid-treated A549 cells at a pre-opti-
mised eVector:target cell ratio of 2:1. Antibodies to CD107b-
FITC and CD107a-APC or IgG1-FITC and IgG1-APC
(Becton–Dickinson) were added directly to the wells. Co-
cultures were incubated for 1 h prior to addition of 1 g/ml
monensin (Sigma) to neutralise intracellular acidity. After a
further 5 h of culture, V2 T-cell expression of CD107a and
CD107b was assessed by Xow cytometry. Alternatively,
cytokine-treated  T-cells were co-cultured overnight with
Daudi cells at target:eVector cell ratios of 1:10, 1:20 and 1:50
in 96-well, V-bottomed tissue culture plates. Cytotoxicity
was assessed using the lactate dehydrogenase assay
(Promega) according to the manufacturer’s instructions. Per-
centage cytotoxicity was calculated against maximum target
cell release using 9% Triton X-100 (Promega).
Blocking experiments
PBMCs were cultured overnight with mycobacteria in the
presence of blocking antibodies to IL-12, IL-1 and TNF-
(R and D Systems) each at 100 g/ml. Also, culture super-
natants from mycobacteria-treated CD4+ cells were pre-
treated for 1 h with blocking antibodies to IL-12, IL-1
and/or TNF- each at 100 g/ml prior to culturing with 
T-cells. Goat IgG1 isotype antibodies (R and D Systems)
were used as controls throughout.
Statistical analyses
Statistical testing was carried out using SigmaStat (SPSS
Inc.) analytical software. Statistical diVerences between
conditions were determined using one-way ANOVA (for
parametric data with equal variances and normal distribu-
tions) or Kruskal–Wallis ANOVA on ranks (for non-para-
metric data) followed by either Holm-Sidak or Dunn’s
Tests, respectively. For some experiments, statistical diVer-
ences between conditions were determined using the stu-
dent’s paired t test. DiVerences with P values less than 0.05
were deemed signiWcant.
Results
 T-cells within mycobacteria-treated PBMCs produce 
granzyme B and TH1 cytokines
To determine the eVects of mycobacterial adjuvants on 
T-cells, we measured activation, proliferation, granzyme
B expression and cytokine production by  T-cells
within BCG-, M. vaccae- and M. obuense-treated PBMCs.538 Cancer Immunol Immunother (2012) 61:535–547
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Preliminary experiments show that live and heat-killed
BCG were equipotent at upregulating CD69 on  T-cells
(supplementary Wg. 1a). Using the pre-optimised concentra-
tions determined in supplementary Wgs. 1a and 1b, heat-
killed BCG, M. vaccae and M. obuense upregulated CD69,
CD25 and HLA-DR expression on  T-cells (Fig. 1a).
Activation was restricted to the V2+ subset, as shown by
upregulated CD69 expression in V2+ but not V1+ cells
(Fig. 1b). The mycobacteria induced proliferation in  T-
cells; however, levels of proliferation against BCG and M.
obuense were markedly higher than against M. vaccae
(Fig. 1c). Changes in the percentage of  T-cells within
PBMCs after 6 days of mycobacterial stimulation were
only minor and not signiWcant (data not shown), suggesting
that other cell types are also proliferating. Moreover, the
mycobacteria upregulated  T-cell expression of gran-
zyme B (Fig. 1d). Analysis of supernatants from mycobac-
teria-treated PBMCs indicated detectable levels of IFN-,
TNF- and IL-10, but relatively low levels of IL-5, IL-4
and IL-2 (data not shown). Intracellular cytokine staining
revealed that  T-cells produced IFN- and TNF-, but not
IL-10 (Fig. 1e).
Mycobacteria-activated V2+ cells have enhanced 
cytotoxicity against tumour cells
Upregulation of granzyme B suggests that mycobacteria-
activated  T-cells may have enhanced cytotoxic proper-
ties. We investigated the ability of mycobacteria-activated
 T-cells to degranulate in the presence of tumour cells.
The Burkitt’s lymphoma cell line Daudi and the lung can-
cer cell line A549 were selected as  T-cell susceptible
and resistant tumour target cells, respectively. Resting
V2+ cells increased CD107a/b expression when exposed
to Daudi but not A549 target cells (Fig. 2a). Mycobacteria-
activated V2+ cells had higher levels of Daudi-induced
CD107a/b expression than untreated V2+ cells (Fig. 2b–
d). Pre-treating A549 cells with zoledronic acid increased
their capacity to induce degranulation in resting V2+ cells
(Fig. 2e). Moreover, mycobacteria-activated V2+ cells had
increased percentage expression of CD107a/b and mean
Xuorescence intensity (MFI) expression of CD107a in
response to A549 cells pre-treated with zoledronic acid
(Fig. 2e). Taken together, mycobacterial adjuvants enhance
 T-cell degranulation in the presence of susceptible
tumours but further treatment was required to expose this
eVect in tumours that are refractory to  T-cell killing.
V2+ cell responses to mycobacteria are dependent 
on CD4+ cells
A range of cell types have been implicated in mediating 
T-cell activation [21–23]. To determine whether the eVect
of BCG, M. vaccae and M. obuense on  T-cells is direct
or mediated by another cell type, the capacity for these
mycobacterial preparations to activate highly puriWed 
T-cells was assessed. PuriWed   T-cells (mean § SD:
98.2 § 1.1%) were not activated by the mycobacteria, as
shown by baseline levels of CD69 expression, cytokine
production and proliferation (Fig. 3a–c). To determine the
cell type required for activation, PBMCs were sequentially
depleted of CD14+ cells (monocytes), CD19+ cells (B-cells)
and CD56+ cells (NK and NKT cells) prior to overnight
stimulation and analysis of CD69 expression on V2+ cells.
Depletion of CD14+ monocytes augmented mycobacteria-
induced V2+ cell expression of CD69 (Fig. 3d) and IFN-
(data not shown), suggesting that in our system monocytes
are inhibitory. Furthermore, co-culturing  T-cells with
monocytes failed to restore their response to the mycobac-
teria (data not shown). Subsequent depletion of CD19+
B-cells had no eVect, whereas depletion of CD56+ NK and
NKT cells reduced mycobacteria-induced CD69 expression
on V2+ cells (Fig. 3d). PuriWed  T-cells were then stimu-
lated with mycobacteria in the presence of either CD56+
cells or a combination of CD4+ and CD8+ cells prior to Xow
cytometric analysis of IFN- production. In the presence of
CD4+/CD8+ cells but not CD56+ cells, the mycobacteria
induced IFN- production by V2+ cells (Fig. 3e). Further-
more, CD4+ but not CD8+ cells were responsible for restor-
ing  T-cell responses to the mycobacterial preparations
(Fig. 3f).
V2+ cells are activated by IL-12, IL-1 and TNF- 
released from mycobacteria-stimulated CD4+ cells
We assessed whether soluble mediators are responsible for
 T-cell activation. Culture supernatants from mycobacte-
ria-stimulated CD4+ cells were added to puriWed  T-cells,
and IFN- production by the V2+ subset was measured.
Results show that culture supernatants from treated CD4+
cells upregulated IFN- production by V2+ cells (Fig. 4a).
Multi-analyte proWling of culture supernatants from myco-
bacteria-treated CD4+ cells revealed the presence of a num-
ber of cytokines (data not shown). Of these, IL-12, IL-1 and
TNF have been previously shown to mediate  T-cell acti-
vation [24–26]. To determine the role played by these three
cytokines, PBMCs were stimulated with mycobacteria in
the presence of blocking antibodies to IL-12, IL-1 and
TNF-. This resulted in a marked reduction in V2+ cell
IFN- production (Fig. 4b), indicating that these cytokines
are key mediators in  T-cell activation. To conWrm this
observation, isolated  T-cells were stimulated with condi-
tioned media from mycobacteria-treated CD4+ cells in the
presence of blocking antibodies to IL-12, IL-1 and TNF-.
Results show that blocking these cytokines reduced V2+
cell IFN- production (Fig. 4c, d). Analysis of these block-Cancer Immunol Immunother (2012) 61:535–547 539
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ing antibodies either individually or in various combina-
tions revealed a combined eVect of all three cytokines
(Fig. 4d).
To conWrm the key role of these cytokines, we measured
 T-cell IFN- production, granzyme B expression and
cytotoxicity in response to recombinant IL-12, IL-1 and
TNF-.  T-cells cultured with all three cytokines resulted
in the greatest IFN- response in the V2+ subset (Fig. 5a).
In accordance with data shown in Fig. 1b, these cytokines
did not induce IFN- production in V2¡   T-cells
(Fig. 5a). IL-12, IL-1 and TNF- upregulated intracellular
expression of granzyme B (Fig. 5b), yet did not induce
degranulation, as shown by baseline levels of CD107a
expression (data not shown).  T-cells activated with these
cytokines showed a marked increase in cytotoxicity against
Daudi target cells (Fig. 5c). Together, these data demon-
strate that IL-12, IL-1 and TNF- can induce eVector
responses in  T-cells.
Fig. 1  T-cells within BCG-, M. vaccae- and M. obuense-treated
PBMCs produce granzyme B and TH1 cytokines. PBMCs were cul-
tured with heat-killed BCG, M. vaccae (Mv) and M. obuense (Mo) and
responses measured within gated  T-cells. Untreated (un) cells were
used as a negative control. a Gating strategy used to identify  T-cells
within PBMCs. Lymphocytes were gated according to size (forward
scatter; FSC) and granularity (side scatter; SSC). Within lymphocytes,
 T-cells were gated as CD3+TCR+. Mean percentages of  T-cells
expressing CD69 (at 24 h; n = 5), CD25 and HLA-DR (both at 48 h;
n = 3) are shown. b Mean percentages of V1+ and V2+ cells express-
ing CD69 (at 24 h; n =3 ) .   c CFSE+ PBMCs were cultured for 6 days
with mycobacteria and proliferation measured within the  T-cell
compartment. Mean percentages of  T-cells proliferating are shown
(n =6 ) .  d Mean Xuorescent intensities (MFI) of granzyme B expres-
sion within  T-cells (at 24 h; n =3 ) .  e Percentages of  T-cells
expressing IFN-, TNF- and IL-10 were measured after 24 h of stim-
ulation. Representative Xow cytometric dot plots from one donor and
mean values for n = 3 are shown. Error bars represent SD. * and **
indicates P values of <0.05 and <0.001, respectively, for statistical
comparisons between treated and untreated cells540 Cancer Immunol Immunother (2012) 61:535–547
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IL-12, IL-1 and TNF- are produced by CD4+ type 1 
myeloid DCs
We have determined the importance of CD4+ cells and their
cytokines in mycobacteria-induced stimulation of  T-cells.
However, CD4 is predominantly expressed on  T-cells,
which typically do not produce IL-12 or IL-1. These cyto-
kines are mostly associated with antigen presenting cells
(APCs) such as monocytes and DCs, which express low
levels of CD4. Therefore, we assessed whether APCs are
present in the CD4+ cell population and measured intracellu-
lar expressions of IL-12, IL-1 and TNF-. Monocytes were
depleted from the PBMC preparations prior to CD4+ cell iso-
lation and therefore were not present in the CD4+ cell popu-
lation. Flow cytometric analysis of CD4, CD3, CD11c,
CD123 and CD14 revealed three populations of cells: T-cells
(CD4highCD3+), myeloid DCs (mDCs; CD4lowCD3¡CD11
c+CD123¡/lowCD14¡) and plasmacytoid DCs (pDCs;
CD4lowCD3¡CD11c¡CD123highCD14¡) (Fig. 6a). Intracel-
lular cytokine staining of mycobacteria-treated CD4+ cells
Fig. 2 BCG, M. vaccae and M. obuense enhance  T-cell cytotoxic-
ity. PBMCs were cultured overnight with heat-killed BCG, M. vaccae
(Mv) and M. obuense (Mo). Untreated (un) cells were used as a nega-
tive control. PBMCs were then co-cultured for 6 h with Daudi or A549
cells at an eVector:target cell ratio of 2:1 and CD107a/b expression
measured within gated V2+ cells. a Mean percentage of V2+ cells
expressing CD107a/b in the absence (media) or presence of Daudi or
A549 target cells (n ¸ 5). b Representative Xow cytometric dot plots
from one donor showing CD107a/b expression on gated V2+ cells.
c Mean percentage of V2+ cells expressing CD107a/b in the absence
(Media) or presence of Daudi target cells (n =5 ) .   d Media test scores
were subtracted from Daudi test scores. Mean values are shown for
n =5 .   Error bars represent SD and * indicates a P value of <0.05 for
statistical comparisons between untreated and treated conditions.
For statistical testing, data were standardised by subtracting the
untreated scores from test scores. e Percentage of V2+ cells express-
ing CD107a/b and mean Xuorescent intensity (MFI) expression of
CD107a on V2+ cells in the presence of zoledronic acid-treated A549
cells. Background levels of degranulation were subtracted from A549-
induced degranulation. Individual experiments for three donors are
shownCancer Immunol Immunother (2012) 61:535–547 541
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revealed that IL-12, IL-1 and TNF- were expressed pre-
dominantly in mDCs (Fig. 6b).
Two types of mDC have been deWned based on
expression of CD123: type 1 (CD123low; mDC1) and
type 2 (CD123¡ mDC2) [27]. Analysis of CD123 expres-
sion revealed that CD123+ but not CD123¡ mDCs pro-
duced IL-12, IL-1 and TNF- in response to the
mycobacteria, suggesting that mDC1s and not mDC2s
are involved in the  T-cell response to these mycobac-
terial preparations (data not shown). Accordingly, the
majority of the mDC population expressed CD1c, a spe-
ciWc marker for mDC1s (Fig. 6c). To conWrm the role of
mDC1s in the  T-cell response to mycobacteria, we
depleted CD1c+ cells from the CD4+ cell population and
assessed the eVects on  T-cell activation. Results show
that when CD1c+ cells were depleted from  T-cell and
CD4+ cell co-cultures, IFN- production by V2+ cells in
response to mycobacteria was lost (Fig. 6d). Taken
together, data suggest that mDC1s are activated by
mycobacteria to produce cytokines that activate  T-cell
responses.
Discussion
As part of our ongoing studies into the mechanisms of
action for BCG, M. vaccae and M. obuense cancer immu-
notherapy, we investigated the potential role of  T-cells.
Our data suggest that BCG, M. vaccae and M. obuense acti-
vate an anti-tumour programme in peripheral blood V2+
 T-cells that is characterised by TH1 cytokine production
and enhanced cytotoxic responses against tumour. More-
over, our data suggest that these responses are indirectly
mediated by IL-12, IL-1 and TNF- from circulating
mDC1s.
 T-cells are highly responsive to mycobacteria; how-
ever, studies have primarily focussed on the stimulatory
capacity of live mycobacterial infections and lysate prepa-
rations. We focussed on live attenuated BCG and heat-
killed M. vaccae and M. obuense, which are preparations of
mycobacteria that are currently used as cancer immunother-
apies in the clinic. Little is known about whether these
preparations can stimulate anti-tumour eVector responses in
 T-cells nor the mechanisms involved. We show here that
Fig. 3 BCG-, M. vaccae- and M. obuense-induced activation of  T-
cells is dependent on CD4+ cells. a  T-cells were cultured overnight
with PMA/I, heat-killed BCG, M. vaccae (Mv) and M. obuense (Mo)
and CD69 expression measured. Representative Xow cytometric histo-
gram plots from one of two donors are shown. Expression for untreated
cells is shown in grey Wll. b Culture supernatants from  T-cells were
screened for their cytokine content using cytometric bead arrays. Mean
values for n = 3 are shown. c  T-cells were cultured with PHA/IL-2,
BCG, Mv and Mo for 6 days and 3H incorporation measured for the
last 16 h of culture. Mean counts per minute (CPM) are shown for
n =2 .  d PBMCs were sequentially depleted of CD14+, CD19+ and
CD56+ cells and stimulated overnight with BCG, Mv and Mo prior to
measuring CD69 expression on gated V2+ cells. Data were standard-
ised by subtracting untreated scores from test scores. Mean values for
n = 3 are shown. e  T-cells were co-cultured overnight with CD56+
cells (top graph) or a combination of CD4+ and CD8+ cells (bottom
graph) in the presence of mycobacteria prior to measuring IFN-
expression on gated V2+ cells. Mean values for n ¸ 2 are shown. f 
T-cells were co-cultured overnight with either CD8+ (top graph) or
CD4+ (bottom graph) in the presence of mycobacteria prior to measur-
ing IFN- expression on gated V2+ cells. Mean values for n =3  a r e
shown. Error bars represent SD542 Cancer Immunol Immunother (2012) 61:535–547
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BCG-, M. vaccae- and M. obuense-activated PBMCs con-
tain  T-cells that produce the TH1 cytokines IFN- and
TNF-, both of which play a demonstrable role in anti-
tumour immunity. Documented eVects of these cytokines
include the following: MHC class I upregulation on tumour
cells, which enhances recognition by cytotoxic  T-cells
[28, 29]; cell cycle blockade and pro-apoptotic signalling,
which hampers tumour cell growth [30, 31]; and TH1 diVer-
entiation, which is critical for generating protective
immune responses against cancer [32, 33]. Evidence sug-
gests that tumours can evade immune responses by upregu-
lating TH2 and downmodulating TH1 immune responses;
indeed, a TH2 bias correlates with disease progression in
certain cancers [34]. Therefore,  T-cell production of
IFN- and TNF- in response to BCG, M. vaccae and
M. obuense immunotherapy could counteract this tumour
escape mechanism and restore the TH1 immune responses
required to promote anti-cancer immunity.
We also investigated the eVects of these mycobacterial
preparations on  T-cell cytotoxicity against tumour cells.
Studies have shown that V2+   T-cells are cytotoxic
towards tumour cells from a broad range of haematologic
and epithelial cancers [14]. Cytotoxicity is primarily depen-
dent on TCR recognition of phosphoantigens and
granzyme/perforin-dependent induction of apoptosis [35].
Also, BCG-speciWc  T-cell lines are cytotoxic towards
Fig. 4 IL-12, IL-1 and TNF- from BCG-, M. vaccae- and M. obu-
ense-treated CD4+ cells activate V2+ cells. a CD4+ cells were
cultured overnight with heat-killed BCG, M. vaccae (Mv) and M. obu-
ense (Mo).  T-cells were then cultured overnight in culture superna-
tant (spnt) from treated CD4+ cells prior to measuring IFN-
expression on gated V2+ cells. IFN- expression was also measured
on  T-cells that had been cultured directly with mycobacteria in the
presence or absence of CD4+ cells. Data were standardised by sub-
tracting untreated scores from test scores. b PBMCs were cultured
overnight with mycobacteria in the presence of blocking antibodies to
IL-12, IL-1 and TNF- each at 100 g/ml. 300 g/ml of isotype
control antibodies were used as a control. IFN- expression on gated
V2+ cells was then measured. c  T-cells were cultured overnight
with spnts from mycobacteria-treated CD4+ cells in the presence of
blocking antibodies to IL-12, IL-1 and TNF- each at 100 g/ml pri-
or to measuring IFN- expression on gated V2+ cells. Representative
Xow cytometric dot plots are shown. d Mean percentage of V2+ cells
expressing IFN- relative to isotype control for experiments con-
ducted in c. Data points are mean values (n = 7 for a; n = 3 for Mv and
Mo in b; n = 2 for BCG in b; and n = 3 for d) where error bars repre-
sent SD and * and ** indicate P values of <0.05 and <0.001, respec-
tively, for statistical comparisons between treated and untreated cellsCancer Immunol Immunother (2012) 61:535–547 543
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tumour cells, suggesting that  T-cells are cross-reactive
[13]. However, the ability of heat-killed mycobacteria to
enhance  T-cell cytotoxicity has not yet been tested. For
the purposes of this study, we used the Burkitt’s lymphoma
cell line Daudi as a model tumour target as this cell line is
routinely used for investigating  T-cell responses against
tumour. We found that mycobacteria-stimulated PBMCs
contained   T-cells with enhanced cytotoxicity against
Daudi cells, as shown by increased degranulation. This
eVect could be explained by upregulation of cytolytic eVec-
tor molecules; indeed, we found that mycobacteria upregu-
lated  T-cell expression of granzyme B, which plays a
critical role in  T-cell cytotoxicity [36]. Taken together,
our data suggest that heat-killed BCG, M. vaccae and
M. obuense enhance the cytotoxic activity of  T-cells in
PBMCs, which may contribute to the anti-tumour properties of
these cancer immunotherapies.
Tumour cell lines that are refractory to  T-cell killing
have been reported; indeed, we found that the A549 tumour
cell line failed to induce  T-cell degranulation. However,
pre-treating A549s with the aminobisphosphonate (ABP)
zoledronic acid increased their capacity to induce  T-cell
degranulation, which conWrms previous studies showing
that ABPs upregulate phosphoantigen expression in
tumours, thus enhancing recognition by V2+  T-cells
[37]. We show that PBMCs exposed to heat-killed myco-
bacteria contain  T-cells with enhanced cytotoxic activity
against zoledronic acid-treated A549s. This suggests that
systemic priming of  T-cells with mycobacteria could be
combined with local treatment of tumours with ABPs,
which would serve to simultaneously increase the visibility
of the tumour whilst augmenting the cytotoxic responses of
circulating eVector cells. The anti-cancer eVects of ABPs
are currently under investigation in lymphoma, myeloma,
prostate cancer and breast cancer [38–40]; however, ABPs
are currently administered via intravenous infusions, which
poses a number of problems. Firstly, ABPs are rapidly
absorbed by the mineral surfaces of bone, thus necessitating
high-dose regimens that are often associated with a range of
complications including pyrexia, nephrotoxicity and elec-
trolyte abnormalities [41]. Intratumoural administration of
ABPs combined with systemic mycobacterial priming may
be a more eVective treatment regimen that reduces these
complications. Secondly, ABPs upregulate phosphoanti-
gens in peripheral blood monocytes, which may render
them susceptible to  T-cell attack and exhaust  T-cell
cytotoxic function before they reach the tumour [42]. Simi-
lar to ABPs, the chemotherapies etoposide, cisplatin and
Fig. 5 IL-12, IL-1 and TNF- induce  T-cell IFN- production and
cytotoxicity. a  T-cells were cultured overnight with diVerent con-
centrations and combinations of IL-12, IL-1 and TNF- prior to mea-
suring IFN- expression on gated V2+ and V2¡ cells. Individual
experiments from three donors are shown. b MFIs for granzyme B
expression on gated  T-cells after overnight culture with 10 ng/ml
each of IL-12, IL-1 and TNF-. Left: Representative Xow cytometric
histogram plots from one donor. Black Wll is the isotype control anti-
body. Numbers are MFIs within the marker shown. Right: MFI values
for n =3 .  c Cytokine-activated  T-cells were co-cultured overnight
with Daudi cells at the target (T) to eVector (E) cell ratios shown. Cyto-
toxicity was assessed by measuring lactate dehydrogenase release into
the culture supernatants. Mean values for n = 3 (T:E 1:50) and n =2
(T:E 1:10 and 1:20) are shown. Untreated (un) cells were used as a neg-
ative control throughout. Error bars represent SD deviations and
* indicates a P value of <0.05 for paired t tests between treatments at
the T:E ratio of 1:50544 Cancer Immunol Immunother (2012) 61:535–547
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doxorubicin have also been shown to increase the suscepti-
bility of tumour cell lines to  T-cell killing [37]. This sug-
gests there may also be potential in combining certain
chemotherapies with BCG, M. vaccae and M. obuense
immunotherapy; indeed, a survival beneWt was reported in
lung cancer patients receiving M. vaccae in combination
with platinum-based chemotherapy [6, 7].
In comparing the three diVerent bacterial preparations,
only minor diVerences were observed between them in
terms of their activity towards  T-cells. Although this
suggests that these diVerent preparations each have the
potential to elicit comparable anti-tumour responses in 
T-cells, the potential for diVerential eVects on other
immune cells remains to be seen. Moreover, the receptors
through which they stimulate mDC1s may diVer, which
may have bearing on potential combinatorial partners. Fur-
ther investigations comparing the induced immune
responses of these three bacterial preparations are therefore
required and are currently underway.
Although  T-cell responses to BCG have been previ-
ously documented, they have been dependent on viable
infection of APCs. For example, Martino et al. [23]
reported that DCs pre-treated with live, but not heat-killed,
BCG activate  T-cells. We found that heat-killed
Fig. 6 IL-12, IL-1 and TNF- are produced by type 1 myeloid DCs.
a Flow cytometry was used to measure the expression of CD4, CD3,
CD11c, CD123 and CD14 on puriWed CD4+ cells. From left to right:
Debris was excluded according to size and granularity using gate
(G) 1. Within the G1 population, CD3 and CD4 expression identiWed
CD4+  T-cells (CD3+CD4high) and non-T-cells (CD3¡CD4low; G2).
Within the G1+G2 non-T-cell population, CD11c and CD123 expres-
sion identiWed myeloid DC (mDC) and plasmacytoid DC (pDC) popu-
lations, both of which did not express CD14. Representative Xow
cytometric dot plots from one of two donors are shown. b CD4+ cells
were cultured overnight with LPS/R848, heat-killed BCG, M. vaccae
(Mv) and M. obuense (Mo). Untreated (un) cells were used as a negative
control. IL-12, IL-1 and TNF- expression was measured on gated
T-cells (CD3+), mDCs (CD3¡CD11c+) and pDCs
(CD3¡CD11c¡CD123high). Mean values for n = 3 are shown (except
TNF-, where n =2 ) .  Error bars represent SD. * and ** indicate
P values of <0.05 and <0.001, respectively, for statistical comparisons
between treated and untreated conditions. c CD1c expression was ana-
lysed on gated mDCs as shown. d Top panels: CD1c+ cells were de-
pleted from the CD4+ cell population. Representative data from one of
three donors are shown. Bottom panels:  T-cells were co-cultured
overnight with CD4+ cells or CD1c-depleted CD4+ cells in the absence
or presence of BCG. Percentage of V2+ cells expressing IFN- was
measuredCancer Immunol Immunother (2012) 61:535–547 545
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mycobacteria can elicit marked  T-cell responses,
suggesting there are alternate mechanisms of activation that
have yet to be reported. Such mechanisms may be more rel-
evant to cancer immunotherapy since the bulk of reconsti-
tuted lyophilised BCG vaccines consist of non-viable
bacilli. Furthermore, BCG is slow growing, thus the eVects
described during live BCG infections are likely to be out-
weighed by those elicited by non-viable BCG. Current
hypotheses suggest that bacterially infected APCs upregu-
late expression of  T-cell-speciWc phosphoantigens. In
support of this, soluble phosphoantigen-speciWc  TCRs
have been shown to selectively bind to BCG-treated but not
untreated DCs [43]. Whether these are mycobacteria-
derived or endogenous phosphoantigens remains unclear.
As shown by Kistowska et al. [44], mycobacterial infec-
tions disrupt isoprenoid biosynthesis in APCs, thus causing
accumulation of endogenous phosphoantigens. Although
mycobacteria-derived and/or endogenous phosphoantigens
presented on infected DCs may activate  T-cells, their
role in  T-cell activation by heat-killed preparations of
mycobacteria is unclear.
We sought to determine the mechanisms by which
heat-killed preparations of mycobacteria induce anti-
tumour immune responses in  T-cells. Our data suggest
that V2+   T-cells are indirectly activated by these
mycobacterial preparations via IL-12, IL-1 and TNF-
produced by mDC1s. Parenthetically, it is interesting to
note that depleting monocytes from our system resulted
in an increase in  T-cell activation, which suggests that
under certain conditions the bacterial preparations could
trigger monocytes to release cytokines that counteract the
eVects of IL-12, IL-1 and TNF-. The newly proposed
mechanism of activation is contrary to previous reports
showing that DCs infected with heat-killed BCG fail to
stimulate  T-cells [23]. However, in this study cyto-
kine-dependent activation of V2+  T-cells by mDC1s
was observed in co-cultures consisting of  T-cells and
CD4+ cells. Therefore, cytokine production by mDC1s in
response to mycobacteria may be dependent on other
cells within the CD4+ population. Accordingly, we found
that  T-cells failed to respond to the heat-killed myco-
bacteria when co-cultured with puriWed monocytes or
mDC1s (data not shown). This is in keeping with previ-
ous reports that pathogen-induced IL-12 production by
DCs is dependent on costimulatory signals such as CD40
ligation, which may be supplied by the T-cell component
of the CD4+ cell population [45]. The mechanisms under-
lying mDC1 cytokine production did not fall within the
scope of this study and investigations are currently
underway.
The observations that heat-killed mycobacteria fail to
activate  T-cells co-cultured with puriWed DCs (i.e. in
the absence of other CD4+ cells) suggests that phosphoan-
tigen recognition is not involved in the  T-cell
responses observed here (Figs. 1,  2) . It i s p ossib le tha t
heat-killing stunts the eYcacy of phosphoantigens or per-
turbs their uptake and processing by mDC1s. Seeing as
cancer immunotherapies use either heat-killed or low-via-
bility preparations of mycobacteria, the newly identiWed
mechanism of indirect cytokine priming compared with
direct phosphoantigen recognition is more clinically rele-
vant. Furthermore, in terms of generating an anti-tumour
 T-cell response, the indirect cytokine-mediated prim-
ing described here may elicit more favourable responses
compared with direct phosphoantigen-mediated activa-
tion. Phosphoantigens are target molecules for  T-cell
cytotoxicity. Therefore, using these target molecules to
prime   T-cells for immunotherapeutic purposes will
cause degranulation, which may exhaust  T-cell cyto-
toxic responses before they encounter tumour. This has
bearing on the use of heat-killed instead of live mycobac-
teria for cancer immunotherapy; indeed, reports have
shown that  T-cells kill APCs harbouring viable bacte-
rial infections [46]. This also has bearing on immunother-
apies that activate  T-cells via phosphoantigens, either
in situ (i.e. via systemic application of ABPs) or ex vivo
(i.e. via adoptive transfer of phosphoantigen-expanded 
T-cells). In contrast, heat-killed mycobacteria, which
indirectly prime  T-cells via cytokines from mDC1s,
may not exhaust  T-cell responses before they encoun-
ter tumour. This eVect could be exploited to improve
immunotherapies so as to avoid exhaustion of  T-cells
prior to tumour inWltration; for example, by combining
systemic administration of mycobacteria with intratumo-
ural administration of ABPs.
In summary, we demonstrate the potential for heat-
killed preparations of BCG, M. vaccae and M. obuense to
prime an anti-tumour eVect in  T-cells. Priming is med-
iated by cytokines from mDC1s and results in production
of TH1 cytokines and increased cytotoxicity towards
tumour cells. Our data provide a potential explanation for
the anti-tumour eVects of these mycobacterial prepara-
tions in vivo. Furthermore, our data suggest that these
immunotherapies can be further developed using combi-
nation therapy, for example, combining systemic BCG,
M. vaccae and M. obuense with localised ABPs or chemo-
therapies that augment  T-cell susceptibility of target
cells. More studies are required to elucidate the full range
of eVects elicited by these mycobacterial preparations,
which are currently underway.
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